{"id":9363,"date":"2021-04-22T15:42:10","date_gmt":"2021-04-22T22:42:10","guid":{"rendered":"https:\/\/depts.washington.edu\/pandemicalliance\/?p=9363"},"modified":"2021-04-23T15:49:23","modified_gmt":"2021-04-23T22:49:23","slug":"mmunogenicity-of-sars-cov-2-vaccine-in-dialysis","status":"publish","type":"post","link":"https:\/\/depts.washington.edu\/pandemicalliance\/2021\/04\/22\/mmunogenicity-of-sars-cov-2-vaccine-in-dialysis\/","title":{"rendered":"Immunogenicity of SARS-CoV-2 Vaccine in Dialysis"},"content":{"rendered":"<ul>\n<li style=\"font-weight: 400\"><i><span style=\"font-weight: 400\">[Pre-print, not peer-reviewed]<\/span><\/i><span style=\"font-weight: 400\"> 89% of 186 dialysis patients developed anti-SARS-CoV-2 spike antibodies following two doses of mRNA vaccines (Pfizer-BioNTech and Moderna). Among patients without prior SARS-CoV-2 infection (n=148), the seropositivity rate was 86%. A majority (70%) of seropositive patients had maximum titers for anti-spike IgG antibodies at least 14 days after the second dose. No significant differences were observed between the two vaccines.<\/span><\/li>\n<\/ul>\n<p><i><span style=\"font-weight: 400\">Lacson et al.\u00a0(Apr 13, 2021). Immunogenicity of SARS-CoV-2 Vaccine in Dialysis. Pre-print downloaded Apr 22 from <\/span><\/i><a href=\"https:\/\/doi.org\/10.1101\/2021.04.08.21254779\"><span style=\"font-weight: 400\">https:\/\/doi.org\/10.1101\/2021.04.08.21254779<\/span><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>[Pre-print, not peer-reviewed] 89% of 186 dialysis patients developed anti-SARS-CoV-2 spike antibodies following two doses of mRNA vaccines (Pfizer-BioNTech and Moderna). Among patients without prior SARS-CoV-2 infection (n=148), the seropositivity rate was 86%. A majority (70%) of seropositive patients had maximum titers for anti-spike IgG antibodies at least 14 days after the second dose. No&#8230;<\/p>\n<div><a class=\"more\" href=\"https:\/\/depts.washington.edu\/pandemicalliance\/2021\/04\/22\/mmunogenicity-of-sars-cov-2-vaccine-in-dialysis\/\">Read more<\/a><\/div>\n","protected":false},"author":8,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"categories":[6],"tags":[67,34],"topic":[31],"class_list":["post-9363","post","type-post","status-publish","format-standard","hentry","category-article-summary","tag-antibodies","tag-clinical-characteristics","topic-vaccines-and-immunity"],"_links":{"self":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/9363","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/comments?post=9363"}],"version-history":[{"count":2,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/9363\/revisions"}],"predecessor-version":[{"id":9378,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/9363\/revisions\/9378"}],"wp:attachment":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/media?parent=9363"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/categories?post=9363"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/tags?post=9363"},{"taxonomy":"topic","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/topic?post=9363"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}